SAGA Diagnostics enters into assay development agreement with AstraZeneca
SAGA Diagnostics, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, has entered into an assay development agreement with AstraZeneca, the global biopharmaceutical company.